Ashley Gallagher

Because of their accessibility in the community, pharmacists can help to deliver balanced and individualized services and address social determinants of health.

The most commonly reported symptoms of long COVID include neurological, muscular, respiratory, and psychological.

Tirzepatide and semaglutide show long-term health care cost savings but, the high cost of the medications offset the savings.

Among the drugs presented, Biktarvy and lenacapavir, teropavimab, and zinlirvimab (LTZ) demonstrate rates of suppression of HIV, and vesatolimod is well tolerated.

These findings challenge the common assumption that older adults might struggle to use more advance medical devices.

This year’s meeting will take place from March 21 to 24 in Nashville, Tennessee.

Additional data shows that an investigational drug, given every 4 months with Apretude, kept viral levels suppressed for patients who were already on stable treatment.

These findings are shared as late-breaking data at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI) being held in San Francisco, California.

Approximately, 62% of respondents stated that the number of active drug shortages could potentially increase by more than 25% within the next 5 years.

Deucravacitinib (Sotyktu) also demonstrates improvements in signs and symptoms, extra-articular manifestations, and patient-reported outcomes.

Patients aged 12 to under 18 saw clinically meaningful regrowth on the scalp, eyebrow, and eyelashes with both high-dose and low-dose treatment.

Approximately 89.7% of patients taking CagriSema achieve the coprimary end point of weight loss of 5% or more compared with 30.3% on the placebo.

Investigators note that low itch and mild disease severity are maintained following a treatment-free interval of 80 days.

Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol levels could potentially be a valuable biomarker for determining the risk of diabetic kidney disease.

In a previous study, results showed that patients taking semaglutide could be at a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION), causing blindness.

The ADjoin long-term extensive study is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis.

Omalizumab-igec is approved to treat moderate to severe persistent asthma in patients 6 years and older whose symptoms are not well controlled with inhaled corticosteroids.

Investigators report that the safety profile is also similar between both drugs.

The feasibility study shows that the STEADY intervention is possible for patients with type 1 diabetes and eating disorders without deteriorating glycemic control.

Currently, there is a gap in treatment for this patient population and intracerebral hemorrhagic stroke is considered an orphan disease.

The approval is the first significant innovation for the delivery of epinephrine for this population in more than 35 years, according to the company news release.

All dosages of semaglutide (Wegovy) under the new program will be available at $499 per month for patients that are uninsured or who do not have coverage for obesity medication.

Investigators found that zonisamide was associated with a reduction in monthly migraine days for pediatric populations.

“The Commission reinforces that obesity is a disease and not due to lack of motivation, willpower, discipline, or laziness,” Robert F. Kushner said.

Denosumab-Bmwo is approved for all indications of the respective reference products, including osteoporosis and high-risk of fracture due to chemotherapy.

However, investigators did not determine the association between compatibility status and loss-of-signal alarms.

Patients in the study could tolerate food allergens more, with fewer adverse events or reactions, compared with multi-allergen oral immunotherapy.

Patients preferred ultrasound stimulation, followed by magnetic stimulation, drugs, electrical stimulation, and brain implantations.

With the disease burden remaining high, CVS Health announces new flu testing and treatment capabilities at approximately 1600 locations in selected states.

The expanded indication now includes patients aged 5 through 11 years in addition to those aged 12 through 65 years.